Cessation of Neoangiogenesis in Alzheimer’s Disease Follows Amyloid-beta Immunization

Kaan E. Biron1,2,3,4,7, Dara L. Dickstein5, Rayshad Gopaul1,2,3,4,6, Franz Fenninger1,2,3,4 & Wilfred A. Jefferies1,2,3,4,6,7,8

1Michael Smith Laboratories, The University of British Columbia, 301-2185 East Mall, Vancouver, British Columbia, V6T 1Z4, Canada, 2The Biomedical Research Centre, University of British Columbia, 2222 Health Sciences Mall, Vancouver, British Columbia, V6T 1Z3, Canada, 3The Brain Research Centre, University of British Columbia, 2211 Wesbrook Mall, Vancouver, B.C. V6T 2B5, Canada, 4Centre for Blood Research, University of British Columbia, 2350 Health Sciences Mall, Vancouver, BC, V6T 1Z3, Canada, 5Department of Neuroscience, Kastor Neurobiology of Aging Laboratories, Mount Sinai School of Medicine, 1 Gustave Levy Place, Box 1065, New York, NY, 10029, USA, 6Department of Zoology, University of British Columbia, 2370-6270 University Blvd., Vancouver, BC, V6T 1Z4, Canada, 7Department of Microbiology and Immunology, University of British Columbia, 1365-2350 Health Sciences Mall, Vancouver, BC, V6T 1Z3, Canada, 8Department of Medical Genetics, 1364-2350 Health Sciences Mall, Vancouver, BC, V6T 1Z3, Canada.

Pathogenic neoangiogenesis in Alzheimer’s disease (AD) is due to amyloid-beta (Aβ) and results in blood-brain barrier (BBB) leakiness in AD. It likely occurs as a compensatory response to impaired cerebral blood flow and provides a strong link between brain vascularity and AD. Aβ immunotherapy is an experimental treatment for AD; however, unexpected negative vascular side effects seen in early human clinical trials demonstrate that our knowledge of Aβ and AD pathogenesis is incomplete. We demonstrate that immunization with Aβ peptides neutralizes the amyloid trigger leading to neoangiogenesis and reverses hypervascularity in Tg2576 AD mice. This process resolves plaque burden suggesting that neoangiogenesis is a key mechanism underlying plaque formation. A meta-analysis demonstrated that hypervascular reversion in vaccinated Alzheimer’s patients. This appears to be the first example of vascular reversion following any therapeutic intervention and supports the conclusion that modulation of neoangiogenesis may repair damage in the AD brain.

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and is the leading cause of dementia in the elderly1. A key neuropathological hallmark of AD is the presence of extracellular neuritic plaques comprised of the amyloid-beta peptide (Aβ)1. According to the amyloid cascade hypothesis, Aβ is produced from the aberrant proteolytic cleavage of the amyloid precursor protein (APP). This results in the overproduction of the 4 kDa Aβ peptide, which is toxic to neurons and synapses either as an insoluble aggregate or as soluble oligomers2. While the amyloid cascade hypothesis implicates Aβ as the main cause of neuronal death in AD it does not address the effect of Aβ on brain vasculature. Recent pre-clinical and clinical studies indicate that vascular risk factors may play a role in the pathogenesis of AD3, specifically resulting in neurovascular dysfunction leading to increased vascular permeability4 and hypervascularization5. Impaired cerebral blood flow (CBF) may be the driver for a compensatory response that results in pathogenic angiogenesis in AD.

AD is currently unpreventable and incurable; however, drugs currently available on the market (reviewed by6) are marginally effective and only treat disease symptoms. There have been several approaches in the development of disease modifying treatments for AD (reviewed by7). The majority of these therapeutic strategies have focused on different aspects of Aβ metabolism including modifying production, preventing aggregation, enhancing elimination and increasing degradation. Aβ immunotherapy is an experimental treatment option that has received considerable attention8. Evidence supporting immunization as a strategy for treating AD comes from preclinical studies using various AD mice models (summarized by9) that were actively immunized with fibrillated Aβ1-42 using two different strategies: preventive (prior to disease onset) or therapeutic (well-after disease onset). Supplementing these finds, we have previously demonstrated that active Aβ immunization restores blood-brain barrier (BBB) integrity in an AD mouse model10.
The overall positive effects of the preclinical Aβ immunization of AD mice encouraged a clinical human trial by Elan/Wyeth in late 1999\(^{11}\). However, unexpected negative vascular side effects\(^{12}\) prevented these therapies from reaching patients. The incomplete clinical trial had mixed results including reduced plaque pathology but persistent tau pathologies\(^{13}\). This demonstrates that our knowledge of Aβ, AD pathogenesis and the blood-brain barrier (BBB) is incomplete. Recently, we proposed the hypothesis that amyloidogenesis promotes extensive neoangiogenesis leading to increased vascular permeability and subsequent hypervascularization in AD\(^{5}\). We further hypothesized that active Aβ immunization might resolve this pathophysiological feature of AD. Here we demonstrate that active immunization with Aβ reverse BBB breakdown at the level of the tight junction (TJ), which creates the physical seal of the BBB. Moreover we found that immunization with Aβ caused a reversion of hypervascularization as indicated by a decrease in microvessel density to levels similar to control mice. While the exact mechanism for Aβ immunotherapy remains to be clarified\(^{14}\), it is clear that the burden of Aβ is reduced in the plasma and may directly or indirectly affect the vasculature. This appears to be the first example of vascular reversion following any therapeutic intervention and provides the proof of concept that neoangiogenesis modulation may repair damage in the AD brain.

### Results

**Immunized Tg2576 mice exhibit reduced Aβ plaque pathology.** Tg2576 (Tg/+ ) mice immunized with Aβ had an overall reduction in parenchymal Aβ plaques (Figure 1). Therapeutically treated Tg/+ with Aβ had a decrease in Aβ plaque pathology (Figure 1B). A complete elimination in Aβ plaques was seen in the Tg/+ mice preventatively immunized with Aβ (Figure 1D). The number of plaques was quantified (Figure 1 and Table 1), by image thresholding, confirming previous results\(^{12}\) showing an overall reduction plaque burden in Aβ immunized Tg2576 mice.

**Immunized Tg2576 mice exhibit reduced cerebrovascular tight junction pathology.** Aβ immunization can restore the BBB integrity\(^{10}\) but the effect on the expression of TJ proteins like ZO-1 is unknown. Using both preventatively and therapeutically immunized mice, with either Aβ or PBS, the morphology of cerebrovascular ZO-1 expression was imaged (Figure 2). Normal ZO-1 expression was visualized as strong, continuous and uninterrupted staining patterns. Indistinguishable regardless of brain region (neocortex or hippocampus), wild-type (+/+ ) mice immunized with either Aβ or PBS had normal ZO-1 staining patterns (Figure 2A–D). Tg/+ mice immunized both preventatively and therapeutically with Aβ exhibited normal ZO-1 expression in the capillaries (Figure 2G and H) similar to +/+ mice. Abnormal expression appeared as weak, punctuate and/or discontinuous staining (white arrowheads; Figure 2E, F, I and J). Tg/+ mice receiving PBS had marked TJ pathology (Figure 2E and F). Interestingly, Tg/+ mice immunized with Aβ displayed some abnormal TJ pathology mainly in larger vessels (Figure 2I and J). The shift in abnormal ZO-1 expression from the capillaries to the larger vessels in the Aβ immunized Tg/+ mice mimicked the observed increase in vascular abnormalities observed in cerebral amyloid angiopathy (CAA) pathology\(^{12}\).

The incidence of TJ pathology was quantified by scoring the percentage of cerebrovasculature with intact versus abnormal ZO-1 morphology. Tg/+ mice immunized with PBS, both preventatively and therapeutically, had a significantly higher percentage of disrupted TJ expression in the neocortex and hippocampus compared to their +/+ counterparts immunized with PBS (Figure 2K–N). Consistent with previous data\(^{10}\), Tg/+ mice preventatively immunized with Aβ displayed a significantly lower percentage of abnormal vascular TJ expression in the neocortex and hippocampus (averaging 10%; \( * p < 0.05\), 2-way ANOVA) compared to their PBS transgenic counterparts (Figure 2K and L). The level of TJ disruption in these mice was similar to +/+ controls injected with both Aβ and PBS. Moreover, TJ pathology in Tg/+ mice immunized therapeutically with Aβ exhibited a significant decrease (averaging 10%; \( * p < 0.05\),

| Table 1 | Aβ immunized Tg2576 mice have reduced plaque count. The number of Aβ plaques and the percentage of Aβ staining relative to the total area of the was quantified based on Figure 1 |
|-----------------|-----------------|-----------------|-----------------|-----------------|
|                | Therapeutically immunized | Preventatively immunized |
| Immunogen      | PBS             | Aβ              | PBS             | Aβ              |
| Aβ plaque count| 504             | 331             | 199             | 55              |
| % of Aβ staining| 0.54            | 0.40            | 0.38            | 0.04            |
Figure 2 | Aβ immunized Tg2576 mice had reduced ZO-1 abnormalities. Cerebrovasculature from +/+ (A–D) and Tg/+ (E–I) mice immunolabeled for ZO-1 (red) and counterstained for DNA (blue) that were immunized with either with PBS (A, B, E and F) or Aβ (C, D, G and H) preventatively or therapeutically. Normal ZO-1 expression in +/+, PBS (A and B), +/+, Aβ (C and D) and Tg/+, Aβ (G and H). Abnormal ZO-1 expression in Tg/+, PBS (E and F) and larger vessels of Tg/+, Aβ (I and J). Scale bar, 20 μm. In all panels, micrographs are representative of three experiments performed with Aβ and PBS treated Tg/+ mice as compared to the +/+. The percentage of cerebral blood vessels with abnormal ZO-1 expression patterns was quantified. Results were consistent between immunization strategies, preventative (K and L) and therapeutic (M and N), and brain regions, cortex (K and M) and hippocampus (L and N). In the preventative strategy: +/+, PBS, n = 3; Tg/+, PBS, n = 4; Aβ, +/+, n = 3; Tg/+, Aβ, n = 3. In the therapeutic strategy: +/+, PBS, n = 4; Tg/+, PBS n = 3; +/+, Aβ, n = 4; Tg/+, Aβ, n = 5. Values are expressed as mean ± SEM and are pooled from 3 separate experiments, *p < 0.05, **p < 0.01, ***p < 0.001.
Figure 3 | Aβ immunized Tg2576 mice have reduced microvascular density. CD105 (green) cerebrovasculature staining regardless of the (A) absence or (B) presence (white arrowheads) of ZO-1 (red) abnormalities. Ubiquitous “hotspot” staining of CD105 in the cortex of a preventatively immunized Tg/+ mouse with either (C) PBS or (D) Aβ. Scale bars, 20 μm. In all panels, micrographs are representative of three experiments performed with Aβ and PBS treated Tg/+ mice as compared to the +/- . Significantly MVD increased in Tg/+, PBS compared to Tg/+, Aβ and +/- , PBS immunized either (E) preventatively (n = 4 for all groups) and (F) therapeutically (+/+, PBS, n = 4; Tg/+, PBS, n = 3; +/- , Aβ, n = 4; Tg/+, Aβ, n = 4). The average brain to body weight ratio was not significant between mice immunized either (G) preventatively (+/+, PBS, n = 5; Tg/+, PBS, n = 4; +/- , Aβ, n = 5; Tg/+, Aβ, n = 3) or (H) therapeutically (+/+, PBS, n = 4; Tg/+, PBS, n = 4; +/- , Aβ, n = 5; Tg/+, Aβ, n = 5). Values are expressed as mean ± SEM and are pooled from 3 separate experiments, *p < 0.05, ***p < 0.001.
Angiogenesis in immunized Tg2576 brains. The microvascular density (MVD) is increased, by extension angiogenesis, in aged Tg2576 mice\(^6\) with disease progression and severity. Does active A\(\beta\) immunization alter the MVD in AD mice? CD105 staining was used to quantify the MVD, which was ubiquitous in the cerebrovasculature regardless of the absence (Figure 3A) or presence (Figure 3B) of TJ abnormalities. Representative examples of the ubiquitous CD105 "hotspot" staining in immunized (preventatively) Tg2576 mice with PBS (Figure 3C) or A\(\beta\) (Figure 3D) demonstrates the MVD qualitatively. Tg/ + mice prevenatively immunized with PBS had over double the MVD (0.4560 ± 0.0072; ***p < 0.001, 2-way ANOVA) compared to their PBS immunized +/+ counterparts (0.1951 ± 0.0130) (Figure 3E). In contrast, the MVD in Tg/+ mice prevenatively immunized with A\(\beta\) was significantly reduced compared to their PBS administered Tg/+ genotype counterparts (0.1972 ± 0.0075; *p < 0.05, 2-way ANOVA) (Figure 3E) and at a similar level observed in +/+ animals. The MVD in the therapeutically treated mice mirrored the observations in the mice immunized prevenatively. Tg/+ mice immunized after disease onset with PBS (0.4939 ± 0.0077) had over double the MVD compared to PBS-immunized +/+ mice (0.2044 ± 0.0222; ***p < 0.001, 2-way ANOVA) (Figure 3F). As seen in the Tg/+ mice immunized prior to disease onset, Tg/+ mice immunized with A\(\beta\) after disease onset also had a significantly reduced MVD (0.2180 ± 0.0130; ***p < 0.001, 2-way ANOVA) compared to Tg/+ mice immunized with PBS (Figure 3F). In short, Tg2576 mice immunized with A\(\beta\) had significantly lower vascular densities (50%) compared to wild-type mice and PBS treated Tg2576 mice. Changes in vascular density were independent of the physical size of the brains (Figure 3G and H).

Furthermore, a Meta-analysis (see Appendix 1) that quantified the endothelial (laminin staining) in the grey and white matter in a vaccinated Alzheimer patient, as originally described by\(^4\), was conducted. Overall, brains from immunized patients had a reduced apparent vascular density compared to relevant controls. In the grey matter, 390 brain endothelia were identified in the untreated AD patient compared to 262 brain endothelia in the immunized AD patient (a 33% reduction after immunization). Similarly, in the white matter, 536 brain endothelia were identified in the untreated AD patient compared to 402 brain endothelia in the immunized AD patient (a 25% reduction after immunization).

Discussion

A\(\beta\) immunotherapy continues to be explored as an experimental treatment option for AD. However, the unexpected negative vascular side effects seen in the early clinical trials of the human AD vaccine have prevented these therapies from reaching AD patients. The recent evidence suggests some optimism on this front\(^16\). Our objective in the current study was to determine if immunization with A\(\beta\) peptides can resolve amyloidogenesis-triggered angiogenesis and hypervascularity in Tg2576 AD mouse. We find a dramatic reversion of hypervascularization follows immunization with A\(\beta\). This appears to be the first example of vascular reversion where vascular density reverts to normal levels following therapeutic intervention. These findings clearly support a vascular angiogenesis model for AD pathophysiology and provide the first evidence that modulating angiogenesis, repairs damage in the AD brain.

BBB dysfunction was initially identified in animal models of AD\(^17\) and was later confirmed as a prominent, though unexplained, clinical feature of AD in patients\(^8\). We recently proposed a new hypothesis that is consistent with the literature relating to the BBB in AD: amyloidogenesis promotes extensive neoangiogenesis leading to increased vascular permeability and subsequent hypervascularization in AD\(^1\). In this model, pathological angiogenesis in AD may occur as a compensatory response to impaired CBF that induces neuroinflammation (releasing pro-angiogenic cytokines) and A\(\beta\), which also acts as a promoter of angiogenesis.

Here we demonstrate that A\(\beta\) immunization modulates pro-angiogenic signals in treated Tg2576 mice that overexpress the human APP695 containing the double missense Swedish mutations (K670N/M671L), which causes early-onset AD. The relative amount of angiogenesis can be quantified through the average microvascular staining densities of CD105 in the brain\(^15,30\). The Tg2576 mice immunized with A\(\beta\) had significantly lower vascular densities (50%) compared to wild-type mice and PBS treated Tg2576 mice. This result was mirrored in a Meta-analysis in vaccinated human AD patients. Again this demonstrates that angiogenic signals are reduced when A\(\beta\) is removed. It is presumed that neuroinflammation, a pathological feature of AD\(^1\), is reduced as a result of amyloid immunotherapy. The removal of the toxic A\(\beta\) species\(^2\) by active immunization would reduce neuroinflammatory cytokines like IL-1\(\beta\), which can induce angiogenesis\(^2\). While the direct involvement of A\(\beta\) in influencing angiogenesis is controversial, recent evidence supports this hypothesis. Cameron et al.\(^2\) demonstrated A\(\beta\) can directly influence angiogenesis via notch signalling. The authors suggest that A\(\beta\) acts as a competitive inhibitor to de-repress signals for angiogenesis.

In vivo (reviewed by\(^9\)) and clinical\(^10\) studies have demonstrated the efficacy of active A\(\beta_{1-42}\) immunotherapy in treating AD and AD-like neuropathology; however, in this report we used A\(\beta_{1-40}\) that replicated the earlier findings\(^8\). Although A\(\beta_{1-40}\) and A\(\beta_{1-42}\) have been cut from the same cloth, they do not share the same biochemical\(^8\) and pathophysiological properties. The soluble A\(\beta_{1-40}\) species is associated with the BBB and therefore CAA\(^11\). The insoluble A\(\beta_{1-42}\) species is mainly found in senile plaques\(^8\). Post active vaccination with A\(\beta_{1-42}\) results in the reduction of A\(\beta_{1-42}\) (reduction in plaques) and evidence exists for the increase in A\(\beta_{1-40}\) in patients\(^29\) (increase in CAA). Furthermore, an increase in cerebrovascular deposits of A\(\beta_{1-42}\) has also been observed\(^8\), which has been interpreted as part of a faulty perivascular drainage mechanism\(^11\).

A side effect observed in the failed clinical A\(\beta\) immunization trial was increased CAA-associated cerebral microhemorrhaging\(^8\), also noted in a variety of AD mouse models after active\(^2\) and passive\(^3\) immunization. Normally, excessive A\(\beta\) accumulation triggers neoangiogenesis resulting in the disruption of the TJs and BBB dysfunction. Microvascular leakage ensues allowing peripheral amyloid to enter the brain and coalesce as neurotoxic amyloid plaques. Cerebrovascular damage is further exasperated by and A\(\beta\) induced ROS derived from NADPH-oxidase\(^1\). During immunization however, various A\(\beta\) clearance mechanisms are activated including opsonization, microglia removal and antibody disaggregation. As A\(\beta\) plaques are dissolved, solubilized A\(\beta\) is removed from the brain parenchyma along perivascular drainage routes\(^8\). Immunization therefore neutralizes the pro-angiogenic signal by stimulating an immune response to A\(\beta\) but other aspects of the disease, once formed, may be unresolved by immunization. For unknown reasons, the perivascular drainage of A\(\beta\) is halted and becomes deposited in the cerebral arteries, resulting in CAA. As noted earlier, the primary A\(\beta\) species found deposited in the CAA-affected vasculature is the more soluble A\(\beta_{1-40}\) believed to be of neuronal origin\(^8\). This model may ultimately explain the emergence of CAA in the failed human AD A\(\beta\) immunization trials\(^11\).

Recently, the anti-proliferative drug bexarotene (Targetrin), an oral anti-cancer agent, has been shown to reduce plaque burden and increase memory performance in animal models of AD\(^2\). This study interprets bexarotene acting on retinoid X receptors to
A final 1 genes that are involved in cell migration, proliferation and apopto-
pal function is ultimately attributed by the reduction of plaque accu-
anti-angiogenic effect by downregulating pro-angiogenic factors.39 These data and those presented herein, therefore directly point towards reversing cerebrovascular angiopathy as a new therapeu-
tic modality for AD.

Methods
Mice. Tg2576 transgenic (Tg+/+) mice were used in this study. These mice express human APP695 containing the Swedish mutation (K670N/M671L), under control of the hamster prion protein promoter (Tacson). Mice were maintained on mixed C57Bl/6J/J background by mating heterozygous Tg2576 males to C57Bl/6J SJ. F1 females. Wild-type (+/+) littermates were used as controls. Mice were fed standard lab chow and water ad libitum and kept under a 12 hour light/dark cycle. All animal procedures were conducted with approval by the University of British Columbia Animal Care Committee.

Aβ vaccination. Aβ vaccination was performed as described by. Briefly, two separate active vaccination strategies were carried out, therapeutic and preventative. In the preventative immunization approach, mice were vaccinated beginning at 6 weeks of age and sacrificed at 12 months of age. Mice used in the therapeutic strategy were vaccinated beginning at 11 months of age and sacrificed at 15 months of age. Aβ peptide was freshly prepared from lyophilized powder for each set of injections. For immunizations, 2 mg of Aβ (human Aβ1-40, Bachem) was added to 0.9 ml of deionized water and thoroughly mixed. Then 100 μL of 10× PBS was added to obtain a final 1× PBS concentration. The solution was vortexed and placed at 37°C overnight until the next day. Aβ1-40(100 μg antigen per injection) or PBS (control) was mixed 1:1 (v/v) with complete Freund’s adjuvant (CFA) for the first immunization. This was followed by a boost with Aβ1-40 (100 μg) or PBS mixed 1:1 (v/v) with incomplete Freund’s adjuvant (IFA) at two weeks and monthly thereafter. From the fifth immunization onward, straight PBS or Aβ were injected. Injections were performed i.p.

Tissue preparation. Tissues were prepared as previously described by. Mice were terminally anesthetized with ketamine/xylazine (100 mg/kg:10 mg/kg) and perfused with PBS for 5 minutes. Brains were then rapidly excised, olfactory bulbs and cerebellum removed, weighed and post-fixed in 4% paraformaldehyde for four days at 4°C. The brains were then imbedded in paraffin and sectioned serially at 5 μm. Paraffin embedding, sectioning, and drewewing were performed by Wax-it Histology Services Inc. (Vancouver). Average brain to body mass ratios were compared amongst the preventative and therapeutically mice.

Immunostaining. Diced paraffin sections underwent antigen retrieval using a conventional stovetop pressure cooker using 20 mM Tris with 0.7 mM EDTA buffer (pH 9.0) for 10 minutes. Cooked sections were then incubated in blocking buffer (25% normal goat serum; 3% BSA; 0.3% Triton X-100, Sigma) for 1 hour at room temperature. Primary antibodies used included rabbit anti-ZO-1 (1:200, Invitrogen), mouse anti-human CD105 (1:20, DAKO), and mouse anti-Aβ1-40 (6E10) (1:2000, Covance). Primary antibody staining was performed overnight in staining buffer. The solution was vortexed and placed at 37°C overnight until the next day. Aβ1-40 (100 μg antigen per injection or PBS) was mixed 1:1 (v/v) with complete Freund’s adjuvant (CFA) for the first two weeks and monthly thereafter. From the fifth immunization onward, straight PBS or Aβ were injected. Injections were performed i.p.

Confocal data sets represented approximately 100 cerebral blood vessels from both sections containing high density (‘‘hotspots’’) CD105 staining were imaged using the 20×/0.45 N-Achroplan objective using the confocal microscopy using the methods described previously. Using the CD105 as a brain vascular endothelial marker of optimal pixel intensity, fluorescence images were acquired and analyzed using the Zeiss LSM510 Meta software. Areas within the brain section containing high density (‘‘hotspots’’) CD105 staining were imaged using the 20×/0.45 N-Achroplan objective using the confocal imaging parameters mentioned previously. The total fluorescent intensity (TFI) in μm² was determined using the software, for each hotspot. The average TFI from four different hotspots per mouse was quantified. The TFI was used as a numerical representation of the total microvessels stained by the CD105 antibody. The microvascular density of the imaged field was expressed as a ratio of the TFI to the total area of the image.

Statistical analysis. All experiments were performed at least three times in triplicate. Statistical comparisons between Tg2576 (Tg+/+) AD mice and wild-type (+/+) control mice were performed with a custom script using MatLab (v7.10.0, R2010a). The edges of the sections were detected using a segmentation algorithm to calculate the total area of each section. A threshold value was then calculated using the Sobel operator, which was tuned to 50% to obtain a binary mask for each section. To quantify Aβ and laminin, the images were first converted into grayscale and then into black and white, using a threshold level of 0.6. Every pixel above this threshold level has been quantified as either Aβ or laminin, respectively. Eight or more connected white pixels, within the mask, were considered as either a plaque or endothelia. The percentage of Aβ staining was calculated by dividing the number of pixels above the threshold by the number of pixels of the total area of the tissue section. Images used in the Meta-analysis have been cropped to remove the original authors figure labelling. The Meta-analysis images were inverted to increase contrast.

Microvessel density quantification. Microvessel density was quantified by confocal microscopy using the methods described previously. Using CD105 as a brain vascular endothelial marker of optimal pixel intensity, fluorescence images were acquired and analyzed using the Zeiss LSM510 Meta software. Areas within the brain section containing high density (‘‘hotspots’’) CD105 staining were imaged using the 20×/0.45 N-Achroplan objective using the confocal imaging parameters mentioned previously. The total fluorescent intensity (TFI) in μm² was determined using the software, for each hotspot. The average TFI from four different hotspots per mouse was quantified. The TFI was used as a numerical representation of the total microvessels stained by the CD105 antibody. The microvascular density of the imaged field was expressed as a ratio of the TFI to the total area of the image.

Statistical analysis. All experiments were performed at least three times in triplicate. Statistical comparisons between Tg2576 (Tg+/+) AD mice and wild-type (+/+) control mice were performed with a custom script using MatLab (v7.10.0, R2010a). The edges of the sections were detected using a segmentation algorithm to calculate the total area of each section. A threshold value was then calculated using the Sobel operator, which was tuned to 50% to obtain a binary mask for each section. To quantify Aβ and laminin, the images were first converted into grayscale and then into black and white, using a threshold level of 0.6. Every pixel above this threshold level has been quantified as either Aβ or laminin, respectively. Eight or more connected white pixels, within the mask, were considered as either a plaque or endothelia. The percentage of Aβ staining was calculated by dividing the number of pixels above the threshold by the number of pixels of the total area of the tissue section. Images used in the Meta-analysis have been cropped to remove the original authors figure labelling. The Meta-analysis images were inverted to increase contrast.

The incidence of tight junction disruption was defined as the average percentage of blood vessels in a given region of brain that displayed abnormal tight junction morphology. Aβ was imaged with a Zeiss LSM 710 Laser Scanning.

Microvessel density quantification. Microvessel density was quantified by confocal microscopy using the methods described previously. Using CD105 as a brain vascular endothelial marker of optimal pixel intensity, fluorescence images were acquired and analyzed using the Zeiss LSM510 Meta software. Areas within the brain section containing high density (‘‘hotspots’’) CD105 staining were imaged using the 20×/0.45 N-Achroplan objective using the confocal imaging parameters mentioned previously. The total fluorescent intensity (TFI) in μm² was determined using the software, for each hotspot. The average TFI from four different hotspots per mouse was quantified. The TFI was used as a numerical representation of the total microvessels stained by the CD105 antibody. The microvascular density of the imaged field was expressed as a ratio of the TFI to the total area of the image.

Statistical analysis. All experiments were performed at least three times in triplicate. Statistical comparisons between Tg2576 (Tg+/+) AD mice and wild-type (+/+) control mice were performed with a custom script using MatLab (v7.10.0, R2010a). The edges of the sections were detected using a segmentation algorithm to calculate the total area of each section. A threshold value was then calculated using the Sobel operator, which was tuned to 50% to obtain a binary mask for each section. To quantify Aβ and laminin, the images were first converted into grayscale and then into black and white, using a threshold level of 0.6. Every pixel above this threshold level has been quantified as either Aβ or laminin, respectively. Eight or more connected white pixels, within the mask, were considered as either a plaque or endothelia. The percentage of Aβ staining was calculated by dividing the number of pixels above the threshold by the number of pixels of the total area of the tissue section. Images used in the Meta-analysis have been cropped to remove the original authors figure labelling. The Meta-analysis images were inverted to increase contrast.

Microvessel density quantification. Microvessel density was quantified by confocal microscopy using the methods described previously. Using CD105 as a brain vascular endothelial marker of optimal pixel intensity, fluorescence images were acquired and analyzed using the Zeiss LSM510 Meta software. Areas within the brain section containing high density (‘‘hotspots’’) CD105 staining were imaged using the 20×/0.45 N-Achroplan objective using the confocal imaging parameters mentioned previously. The total fluorescent intensity (TFI) in μm² was determined using the software, for each hotspot. The average TFI from four different hotspots per mouse was quantified. The TFI was used as a numerical representation of the total microvessels stained by the CD105 antibody. The microvascular density of the imaged field was expressed as a ratio of the TFI to the total area of the image.

Statistical analysis. All experiments were performed at least three times in triplicate. Statistical comparisons between Tg2576 (Tg+/+) AD mice and wild-type (+/+) control mice were performed with a custom script using MatLab (v7.10.0, R2010a). The edges of the sections were detected using a segmentation algorithm to calculate the total area of each section. A threshold value was then calculated using the Sobel operator, which was tuned to 50% to obtain a binary mask for each section. To quantify Aβ and laminin, the images were first converted into grayscale and then into black and white, using a threshold level of 0.6. Every pixel above this threshold level has been quantified as either Aβ or laminin, respectively. Eight or more connected white pixels, within the mask, were considered as either a plaque or endothelia. The percentage of Aβ staining was calculated by dividing the number of pixels above the threshold by the number of pixels of the total area of the tissue section. Images used in the Meta-analysis have been cropped to remove the original authors figure labelling. The Meta-analysis images were inverted to increase contrast.
19. Holley, J. E., Newcombe, J., Whatmore, J. L. & Gutowski, N. J. Increased blood vessel density and endothelial cell proliferation in multiple sclerosis cerebral white matter. *Neurosci Lett* **470**, 65–70 (2010).

20. Barresi, V., Cerasoli, S., Vitarelli, E. & Tucciari, G. Density of microvessels positive for CD105 (endoglin) is related to prognosis in meningiomas. *Acta Neuropathol*** **114**, 147–156 (2007).

21. Streit, W. J., Mrak, R. E. & Griffin, W. S. Microglia and neuroinflammation: a pathological perspective. *J Neuroinflammation* **1**, 14 (2004).

22. Benilova, I., Karran, E. & De Strooper, B. The toxic Abeta oligomer and Alzheimer’s disease: an emperor in need of clothes. *Nat Neurosci*** **15**, 349–357 (2012).

23. Pogue, A. I. & Lukiw, W. J. Angiogenic signaling in Alzheimer’s disease. *Neuroreport*** **15**, 1507–1510 (2004).

24. Cameron, D. J. *et al*. Alzheimer’s-Related Peptide Amyloid-beta Plays a Conserved Role in Angiogenesis. *PLoS One* **7**, e39598 (2012).

25. Nicoll, J. A. *et al*. Neutrophil pathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. *Nat Med*** **9**, 448–452 (2003).

26. Harrison, R. S., Sharpe, P. C., Singh, Y. & Fairlie, D. P. Amyloid peptides and proteins in review. *Rev Physiol Biochem Pharmacol*** **159**, 1–77 (2007).

27. Suzuki, N. *et al*. High tissue content of soluble beta 1–40 is linked to cerebral amyloid angiopathy. *Am J Pathol*** **145**, 452–460 (1994).

28. Prelli, F., Castano, E., Glenner, G. G. & Frangione, B. Differences between vascular and plaque core amyloid in Alzheimer’s disease. *J Neurochem*** **51**, 648–651 (1988).

29. Patton, R. L. *et al*. Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer’s disease patients: a biochemical analysis. *Am J Pathol*** **169**, 1048–1063 (2006).

30. Nicoll, J. A. *et al*. Abeta species removal after abeta42 immunization. *J Neuropath Exp Neurol*** **65**, 1040–1048 (2006).

31. Boche, D. *et al*. Consequence of Abeta immunization on the vasculature of human Alzheimer’s disease brain. *Brain*** **131**, 3299–3310 (2008).

32. Wilcock, D. M. *et al*. Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathologies and protects from neuron loss in two mouse models of Alzheimer’s disease. *J Neurosci*** **29**, 7957–7965 (2009).

33. Racke, M. M. *et al*. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. *J Neurosci*** **25**, 629–636 (2005).

34. Park, L. *et al*. NADPH-oxidase-derived reactive oxygen species mediate the cerebrovascular dysfunction induced by the amyloid beta peptide. *J Neurosci*** **25**, 1769–1777 (2005).

35. Weller, R. O., Preston, S. D., Subash, M. & Carare, R. O. Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease. *Alzheimers Res Ther*** **1**, 6 (2009).

36. Herzig, M. C., Van Nostrand, W. E. & Jucker, M. Mechanism of cerebral beta-amyloid angiopathy: murine and cellular models. *Brain Pathol*** **16**, 40–54 (2006).

37. Cramer, P. E. *et al*. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. *Science*** **335**, 1503–1506 (2012).

38. Qu, L. & Tang, X. Bexarotene: a promising anticancer agent. *Cancer Chemother Pharmacol*** **65**, 201–205 (2010).

39. Yen, W. C., Prudente, R. Y., Corpuz, M. R., Negro-Vilar, A. & Lamph, W. W. A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours. *British journal of cancer*** **94**, 654–660 (2006).

40. Hsiao, K. *et al*. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. *Science*** **274**, 99–102 (1996).

**Acknowledgements**

The authors thank: Dr. Cheryl Pfeifer and Ms. Lonna Munro for critical reading and editing the manuscript; Kevin Hodgson of the UBC BioImaging Facility for technical advice; the Canadian Institute for Health Research for funding.

**Author contributions**

Conceived and designed the experiments: K.E.B., D.L.D., W.A.J. Performed the experiments: K.E.B., D.L.D., W.A.J. Performed the analysis: K.E.B., D.L.D., W.A.J. Wrote the paper: K.E.B., D.L.D., W.A.J.

**Additional information**

Supplementary information accompanies this paper at http://www.nature.com/scientificreports

**Competing financial interests:** The authors declare no competing financial interests.

**License:** This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/

**How to cite this article:** Biron, K.E., Dickstein, D.L., Gopaul, R., Fenninger, F. & Jefferies, W.A. Cessation of Neoangiogenesis in Alzheimer’s Disease Follows Amyloid-beta Immunization. *Sci. Rep.* **3**, 1354; DOI:10.1038/srep01354 (2013).